Despite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. One potential limitation of the current treatment paradigm is the lack of effective therapies to optimize reperfusion after ischemia and prevent reperfusion-mediated injury. Experimental studies indicate that this process accounts for up to 50% of the final infarct size, lending it importance as a potential target for cardioprotection. However, 
D
espite therapeutic advances, acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide. Sustained research efforts over the years have achieved numerous milestones (1) (2) (3) . Despite the success stories, the rate of progression to heart failure and related complications remains unacceptably high (3, 4) . One potential limitation is the lack of effective therapies to optimize reperfusion after ischemia and prevent reperfusion-mediated injury. This has been termed reperfusion injury, or alternatively ischemiareperfusion injury (5) . Experimental studies indicate that this process accounts for up to 50% of the final infarct size, lending it importance as a potential target for cardioprotection (6) . However, multiple therapeutic approaches have failed to translate from the bench to the bedside, or have shown therapeutic potential in early phase II trials (7) (8) (9) 
REPERFUSION INJURY
The phenomenon of reperfusion injury was first born out of a demonstration that post-ischemic restoration of blood flow had several potential deleterious effects, including myocardial stunning (13) . The idea of harm from reperfusion was later supported by demonstration of smaller infarct size with slower, low-pressure reperfusion over standard abrupt reperfusion at normal pressure, a benefit gained from interventions applied after the ischemic period rather than within it (14) . Many other signaling cascades and processes within and outside the mitochondria are concomitantly activated during ischemia and reperfusion and are likely to contribute to infarct size. For the scope of this review, we focused only on the mechanisms involving a change in permeability in the mitochondrial membrane for which a drug had been tested in both pre-clinical and clinical studies.
During ischemia, intracellular Na

ISCHEMIC PRE-CONDITIONING
This discovery that reperfusion could be a doubleedged sword (13) spawned a new wave of experiments. One landmark study described how repeating cycles of alternating ischemia and reperfusion performed prior to prolonged coronary artery occlusion significantly reduced final infarct size in dogs (even when total ischemia time was longer); this created the new field of "pre-conditioning" (21), replicated in numerous laboratories around the world (22-24).
A "second window" of cardioprotection was also shown to begin 24 h after the initial window of protection. In 1 study, infarct size was reduced in rabbits subjected to four 5-min cycles of coronary artery occlusion prior to 24-h recovery, followed by a 30-min reocclusion (25) or a 90-min reocclusion (26) . The clinical translational value of having identified the second window of cardioprotection, however, is still uncertain.
Interestingly, limitations of the preconditioning strategy became apparent quite rapidly. Cardiac protection was seen when occlusion/ reperfusion cycles were performed prior to 40-or 60-min occlusion, but not prior to 90- (27) or 180-min (21) occlusion. These experiments highlight that the efficacy of pre-conditioning is limited to a specific window of duration of ischemia. Hence the difficulty in translation to humans: it is difficult to determine exactly when a patient starts experiencing ischemia, and usually by the time the patient is seen in the hospital, the ischemia has been ongoing for hours.
ISCHEMIC POST-CONDITIONING
An additional step forward in the field was provided 
PHARMACOLOGIC ISCHEMIC CONDITIONING
The study of the events occurring in ischemic pre-and post-conditioning has stimulated a large number of investigations into the signaling and mechanisms. 
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MMP Inhibitors in AMI
These studies provided not only a better understanding but also insight into potential therapeutic targets.
The hypothesis that a drug given at a specific time during reperfusion could reduce infarct size and improve on the benefit of reperfusion became the search for the "holy grail" in cardiology (6) . For the purpose of this review, we will focus on CsA and other drugs targeted at inhibiting the permeability of the mitochondrial membrane during ischemia and reperfusion. CsA and other drugs with similar mechanism had shown promising pre-clinical data, which was then studied in phase II and III clinical trials.
PRECLINICAL STUDIES OF CSA
Finding a targeted medication that could be given during a specific time during ischemia or reperfusion, in an effort to reduce infarct size, become the goal of many therapeutic attempts (6) . CsA is a cyclic nonribosomal peptide that was first extracted from the Norwegian soil fungus Tolypociadium inflatum in 1969 (33, 34 given "less than 10 min before direct stenting," and a Cyclosporine, MTP-131, and TRO40303 inhibit mitochondrial membrane permeability and prevent cell death. mPTP ¼ mitochondrial permeability transition pore.
Trankle et al. Reduced by 40%-50%
AMI ¼ acute myocardial infarction; ATP ¼ adenosine triphosphate; CsA ¼ cyclosporine A; LVEF ¼ left ventricular ejection fraction; mPTP ¼ mitochondrial permeability transition pore.
Trankle et al. Being an open-label study, it is reasonable to assume that patients incurred no delay in the no-treatment arm, better described as a no-treatment or no-delay IU ¼ international units; PCI ¼ percutaneous coronary intervention; Q ¼ quartile.
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internal mitochondrial membrane and reduce ROS production in response to multiple chemical stressors. When infused prior to the onset of ischemia and repeated 5 min prior to reperfusion in an in vivo rat model, infarct size showed a 10% reduction (57);
isolated rat heart studies later suggested an infarctsparing effect when infused at the time of reperfusion after being subjected to 20 min of global ischemia (58) . Using this agent, infarct size was also reduced in the sheep model when infused after Table 3) .
It is indeed apparent that CsA given as a single dose of 2.5 to 10 mg/kg intravenously 10 to 15 min prior to reperfusion in animal models significantly reduces infarct size, preserving functional myocardium and global systolic function (37, 40, 43) . As such, the phase II pilot study published in 2008 was able to largely reproduce the benefits of CsA in patients with STEMI by administering the drug up to 10 min prior to reperfusion with direct stenting (47) . It is worth Trankle et al. open-label design with PROBE trial endpoint assessment, as in the CYCLE study, but with a clearly specified treatment delay of 10 min in the CsA arm and no delay in the control arm, would be advisable, with the understanding that this model was never tested in pre-clinical studies. In the animal models, CsA was given 10 min before reperfusion, but not at the cost of prolonging ischemia; therefore, both arms had the same duration of ischemia. In the clinical setting, either a shift would be made such that CsA is given before angiography, or it must necessarily prolong ischemia by 10 min in the CsA arm. Therefore, a question that could be tested in animal models would be whether extending ischemia to allow for CsA steady states is superior to immediate reperfusion.
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